Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism.
Designer benzodiazepines provide an attractive alternative to prescribed benzodiazepines for abuse purposes as they are readily available via the Internet without control. Metizolam was ordered via the Internet and a 2 mg blue tablet was orally administered to a 54-year-old man. Urine samples were collected over 6 days in polypropylene tubes. After liquid/liquid extraction at pH 9.5, metizolam was analyzed by ultra-performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UPLC-ESI-MS/MS) using a standard method devoted to benzodiazepines, and ions transitions, at m/z 328.9 > 275.0 and 328.9 > 300.0. Metizolam was detectable in hydrolyzed urine during the 46-h period, with concentrations always lower than 11 ng/mL. About 0.3% of the initial dose was excreted in urines as total unchanged metizolam during the first 24 h. The most relevant potential CYP- and UGT-dependent metabolites of metizolam were investigated in vitro using human liver microsome incubation and, subsequently, liquid chromatography coupled with quadrupole-time of flight mass spectrometry (UHPLC-Q-TOF-MS) analysis. Three mono-hydroxylated metabolites were produced including a hydroxylation compound at the 2-ethyl moiety of metizolam (M1) as quantitatively main metabolite, and a N-hydroxymetiazolam (M2). The structure of the third metabolite (M3) could not be elucidated because of a too low experimental production rate. Two authentic urine samples were analyzed using the same analytical method to search for metabolites of metizolam. M1, together with its glucuronide (M1-Glu), and M2 were observed in urine at the 8 h mark, whereas only M1 and M1-Glu were still detected in urine at 30 h post administration. Copyright © 2016 John Wiley & Sons, Ltd.
X-Pertise Consulting, Oberhausbergen, France.|Institut de medicine légale, Strasbourg, France.
Pascal
P
Kintz
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France.|Univ. Lille, EA 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Lille, France.
Camille
C
Richeval
Institut de medicine légale, Strasbourg, France.
Carole
C
Jamey
Institut de medicine légale, Strasbourg, France.
Alice
A
Ameline
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France.|Univ. Lille, EA 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Lille, France.
Delphine
D
Allorge
CHU Lille, Unité Fonctionnelle de Toxicologie, Lille, France.|Univ. Lille, EA 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, Lille, France.
Jean-Michel
JM
Gaulier
Institut de medicine légale, Strasbourg, France.
Jean-Sébastien
JS
Raul
D001569:Benzodiazepines / Q000378:metabolism / Q000652:urine; D002492:Central Nervous System Depressants / Q000378:metabolism / Q000652:urine*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D015198:Designer Drugs / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D015813:Substance Abuse Detection / Q000379:methods*; D053719:Tandem Mass Spectrometry / Q000379:methods*
D002492:Central Nervous System Depressants; D015198:Designer Drugs; C000627028:metizolam; D001569:Benzodiazepines
HLMs; benzodiazepines; metabolism; metizolam; urine